VANCOUVER, BC, Sept. 19, 2024 /CNW/ – The Honourable Jonathan Wilkinson, Minister of Energy and Natural Resources, and Ranj Pillai, the Premier of Yukon, will make a funding announcement in support of critical minerals infrastructure projects. A media availability will follow.

Date: September 20, 2024

Time: 10:30 a.m. PT

All accredited media are asked to pre-register by emailing media@nrcan-rncan.gc.ca. A dial-in line is available for media and will be provided upon registration.

Follow us on LinkedIn

SOURCE Natural Resources Canada

VICTORIA, BC, Sept. 19, 2024 /CNW/ – Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting a poster at the upcoming 20th International Symposium on Digestive Endoscopy (“ISDE”) World Congress for Esophageal Diseases to be held in Edinburgh, Scotland on September 22-24, 2024.

The event is a premier global conference focused on advancing knowledge and collaboration in the field of digestive endoscopy.

Presentation Details:

The presentation, which will feature data from cohorts one through four from the RESOLVE trial, will also be available on Eupraxia’s website at:

https://eupraxiapharma.com/our-science/clinical-trials-and-publications/default.aspx.

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia’s DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia’s EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (“EoE”). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company’s website at: www.eupraxiapharma.com.

Notice Regarding Forward-looking Statements and Information

This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “is expected”, “expects”, “suggests”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes”, “potential” or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the details of the Company’s presentation at the upcoming 20th ISDE World Congress for Esophageal Diseases; the Company’s product candidates, including their expected benefits to patients with respect to safety, tolerability; efficacy and duration; the results gathered from studies and trials of Eupraxia’s product candidates; the potential for the Company’s technology to impact the drug delivery process; potential market opportunity for the Company’s products; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia’s management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company’s ability to obtain positive results from the Company’s research and development activities, including clinical trials; and the Company’s ability to protect patents and proprietary rights. Although Eupraxia’s management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company’s limited operating history; the Company’s novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company’s current license agreement may not provide an adequate remedy for its breach by the licensor; the Company’s technology may not be successful for its intended use; the Company’s future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company’s clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company’s ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company’s operations; the Company’s restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company’s common share price; and other risks and uncertainties described in more detail in Eupraxia’s public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-to-present-at-20th-isde-world-congress-for-esophageal-diseases-302253679.html

SOURCE Eupraxia Pharmaceuticals Inc.

Backbase implementation marks innovation milestone for Arizona credit unions

PHOENIX, Sept. 19, 2024 /PRNewswire-PRWeb/ — OneAZ Credit Union is launching a transformative strategic partnership with Backbase, the creator of the Engagement Banking Platform, to modernize the credit union’s technology architecture. Through Backbase’s platform, OneAZ will deliver a simplified and streamlined banking experience, expanding beyond financial service offerings to include insurance, real estate and other lifestyle-related offerings and creating a one-stop-shop for members.

“By partnering with Backbase, OneAZ Credit Union is reaching a major milestone in our digital transformation,” said Sandeep Uthra, EVP Chief Technology Officer at OneAZ. “This innovative upgrade to our technology platform will significantly enhance the member experience across our digital landscape, allowing us to scale innovation faster and deliver more value to members. We are committed to adopting innovative solutions that help members achieve their dreams and drive greater prosperity to the communities we serve. With Backbase, we’re ten steps closer to achieving that.”

“This strategic partnership with Backbase puts OneAZ in control of our own digital destiny,” said Brandon Michaels, President & CEO of OneAZ Credit Union. “The banking landscape is changing radically as consumers demand a seamless experience matched with simplicity and speed. Backbase’s Engagement Banking Platform will be the backbone of our digital transformation, allowing OneAZ to modernize our banking infrastructure and empower us to deliver more innovative solutions to serve our members.”

“Partnering with OneAZ highlights Backbase’s commitment to the banking market and showcases the momentum we’re seeing worldwide in providing financial institutions with the platform needed to deliver tailored, hyper-personalized experiences.” said Iman Ghodosi, Senior Vice President North America, Backbase. “By leveraging our Engagement Banking Platform, OneAZ is elevating member experience and driving innovation. We’re excited to be part of OneAZ’s critical digital transformation journey, and are proud to have another marquee credit union customer working with Backbase.”

Backbase is at the forefront of revolutionizing the banking industry by leading the shift towards an engagement banking model that prioritizes journey orchestration for both financial institutions and their customers. The Backbase Engagement Banking Platform is helping to empower OneAZ on their digital transformation journey and put customer-centricity at the core.

Integrating Backbase into their systems will allow OneAZ to achieve:

Simplification: Backbase will unify our IT architecture around a single platform, simplifying the experience for associates and members.Agility and speed: By connecting all our applications and programs into an integrated platform, we’ll be able to scale new integrations faster, delivering more value to members.Control: The flexibility of the platform allows for more control of its own future digital roll-outs as well as grants the ability to provide an “instant banking experience” for its members of all generations.

OneAZ is committed to driving growth through innovative solutions. By collaborating with Backbase, OneAZ is standing at the cutting edge of advanced technology and setting the standard for other institutions to follow. This partnership will allow OneAZ to unleash the full potential of engagement banking to deliver a personalized member experience as well as improve internal employee operations.

About OneAZ Credit Union
Serving Arizona since 1951, OneAZ Credit Union is a financial powerhouse managing over $3.4 billion in assets and serving over 200,000 member-owners and 12,000 business owners across 20 branches statewide. We are committed to inspiring dreams and driving prosperity and community growth through innovative and high-quality personal and business banking solutions. At OneAZ, it’s all about banking for the people, not for profit. Discover more at OneAZcu.com. Insured by NCUA. Join us in driving prosperity and building a brighter tomorrow for Arizona.

About Backbase
Backbase is on a mission to re-architect banking around your members.

Backbase created the Backbase Engagement Banking Platform – a unified platform with your members at the heart, freeing credit unions to empower their members in their financial lives. From onboarding, to servicing, loyalty and loan origination, our single platform — open and frictionless, with ready-to-go apps — improves every aspect of your members’ experience. Built from the ground up to serve your members, our Engagement Banking Platform plugs into 10+ existing core banking systems and comes pre-integrated with specialist fintechs, so your credit union can innovate at speed.

Industry analysts Forrester, Javelin, Aite, Gartner, Celent, and IDC continuously rank Backbase as one of the leaders in digital transformation. Over 120 credit unions and banks around the world have embraced the Backbase Engagement Banking Platform – including Blue Federal Credit Union, ENT Credit Union, Navy Federal Credit Union, SchoolsFirst Federal Credit Union, State Employees’ Credit Union, United Federal Credit Union, Washington State Employee Credit Union, Westerra Credit Union, and Wildfire Credit Union.

Backbase is a private fintech company, founded in 2003 in Amsterdam (Global HQ), and proudly serving the American market from our Americas HQ in Atlanta.

Media Contact

Candace Youde, OneAZ Credit Union, (480) 442-4868, candace@proofpragency.com, https://www.oneazcu.com/

View original content to download multimedia:https://www.prweb.com/releases/oneaz-credit-union-announces-strategic-partnership-with-backbase-302253528.html

SOURCE OneAZ Credit Union